Video
Dr. Yimer on Long-Term Proteasome Inhibition in Newly Diagnosed Myeloma
Author(s):
Habte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).
Habte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).
Related Videos
Related Content
